Zentalis Pharmaceuticals (NASDAQ: ZNTL) insider transactions

In the twelve months to 10 November 2026, executives and directors of Zentalis Pharmaceuticals reported 10 open-market sales of 7,555,372 shares ($10.1m) and 2 open-market purchases of 10,794,973 shares ($22.9m), by 5 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Zentalis Pharmaceuticals shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
30 September 2026	Bruns Ingmar	Chief Medical Officer	Grant or award	+9,727	$2.18	43,059	Form 4
14 August 2026	Walters William Thurman	—	Open-market purchase	+4,335,000	$3.50	17,844,973	Form 4
16 June 2026	Myers Scott Dunseth	Director	Grant or award	+57,100	—	395,895	Form 4
16 June 2026	Walker Luke Nathaniel	Director	Grant or award	+57,100	—	201,384	Form 4
16 June 2026	Johnson David Michael	Director	Grant or award	+57,100	—	307,521	Form 4
16 June 2026	Skvarka Jan	Director	Grant or award	+57,100	—	264,254	Form 4
16 June 2026	Kariuki Enoch	Director	Grant or award	+57,100	—	194,465	Form 4
26 May 2026	Campbell Shannon	Director	Grant or award	+114,200	—	114,200	Form 4
10 February 2026	Vultaggio Vincent	PAO and PFO	Open-market sale, 10b5-1 plan	−6,894	$2.42	146,506	Form 4
9 February 2026	Eastland Julia Marie	CEO & President	Open-market sale	−889	$2.39	79,133	Form 4
9 February 2026	Bruns Ingmar	Chief Medical Officer	Open-market sale	−335	$2.39	33,332	Form 4
9 February 2026	Vultaggio Vincent	PAO and PFO	Open-market sale, 10b5-1 plan	−3,379	$2.39	153,400	Form 4
6 February 2026	Eastland Julia Marie	CEO & President	Open-market sale	−7,866	$2.43	80,022	Form 4
6 February 2026	Bruns Ingmar	Chief Medical Officer	Open-market sale	−2,962	$2.43	33,667	Form 4
6 February 2026	Vultaggio Vincent	PAO and PFO	Open-market sale, 10b5-1 plan	−29,951	$2.43	156,779	Form 4
3 February 2026	Vultaggio Vincent	PAO and PFO	Open-market sale, 10b5-1 plan	−556	$2.52	186,730	Form 4
2 February 2026	Vultaggio Vincent	PAO and PFO	Open-market sale, 10b5-1 plan	−2,540	$2.55	187,286	Form 4
31 December 2025	Walters William Thurman	—	Open-market purchase	+6,459,973	$1.20	13,509,973	Form 4
15 December 2025	Goel David E.	—	Open-market sale	−7,500,000	$1.33	6,459,973	Form 4
17 June 2025	Myers Scott Dunseth	Director	Grant or award	+57,603	—	338,795	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Zentalis Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.